If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
164
results.
Updated on
16/02/2026 [07:24:00]
Results 100 to 125 of 164
Absstract of: WO2025257397A1
The inventors have investigated the use of an attenuated B. pertussis strain as a live vehicle for the expression of heterologous antigens (e. g. SARS-CoV-2 N-protein) through the auto-transporter SphB1 secretion machinery. The passenger domain of Sph1 was replaced by N- protein in an expression cassette containing the pertactin signal peptide coding region and promoter region. The chimeric protein was successfully produced and secreted to the extracellular medium. Nasal administration of the live recombinant strains triggered a specific systemic cell-mediated response against N-protein. These results support the use of live attenuated B. pertussis strains as a potential vaccine platform for heterologous antigen delivery.
Absstract of: US2025381207A1
Compositions that contain flavonoids such as hesperidin, quercetin, hesperetin, and rutin and methods of treating viral diseases such as coronavirus (e.g., SARS COV-2) infection, influenza virus infection, rhinovirus infection, and human metapneumovirus infection.
Absstract of: US2025381265A1
Provided herein are mutant coronavirus spike proteins, methods of making and using, vaccines, vectors and nucleic acids, comprising at least one of the following modifications: a short flexible peptide linker or a rigid peptide linker in place of the furin cleavage site loop to genetically link an S1 and S2 subunit; at least one additional disulfide bond; or 1, 2, 3, 4, or 5 proline mutations for greater trimeric stability, wherein the mutant coronavirus spike protein has: a higher stability or a higher level of expression when compared to a non-modified coronavirus spike protein. Coronavirus is SARS, MERS, 229E (alpha), NL63 (alpha), OC43 (beta), HKU1 (beta), SARS-CoV-2, or an emerging variant thereof. Cunent SARS-CoV-2 variants include, e.g., B.1.1.7, B.1.1.7 with E484K, B.1.135, B.1.351, P.1, B.1.427, D614G, B.1.1351, or B.1.429, Lambda (i.e., C.37), Mu (i.e., B.1.621), Omicron (B.1.1.529) or a variant (including but not limited to BA.1, BA.2, or BA.3) thereof, and others.
Absstract of: US2025382353A1
The present invention includes monoclonal antibody or antigen-binding fragment thereof, methods of using, detection, recombinant vectors, host cells, kits, variants, and pharmaceutical compositions that include the antibody or antigen-binding fragment thereof that is cross-reactive and binds to different variants of a Spike protein of SARS-CoV-2 (SARS2-S).
Nº publicación: AU2024266327A1 18/12/2025
Applicant:
AG IP COMPANY PTY LTD
AG IP COMPANY PTY LTD
Absstract of: AU2024266327A1
The invention relates, inter alia, to methods of preparing a garlic oil, garlic oils produced using the method, pharmaceutical compositions comprising the garlic oil and uses of the garlic oil in the treatment of viral infections such as SARS-COV-2 and influenza A. The methods of preparing a garlic oil comprise the steps of: a) processing a portion of a garlic plant to increase its surface area; b) ageing the portion of the garlic plant for at least 18 months to provide an aged garlic, which does not comprise addition of ethanol; and c) separating the garlic oil in the aged garlic. Step c) may be performed using spinning cone distillation or supercritical fluid extraction, at a temperature below 110 °C, or such that the pressure (atmospheres) divided by the temperature (degrees Kelvin) is equal to or less than about 0.0026.
BOPI
Electronic site
